USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
NEOCLONE BIOTECHNOLOGY INTERNATIONAL
Address:
1202 Ann St
MADISON, WI 53713-2410
Phone:
N/A
URL:
N/A
EIN:
139198167
DUNS:
19933295
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,640,419.00 6
SBIR Phase II $206,777.00 1
STTR Phase I $190,591.00 1

Award List:

BIOMARK SCRN W REVOLUTIONARY NEOAB ANTIBODIES

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Rachel Kravitz
Abstract:
N/a

Novel Platform Technology for Developing Therapeutic Human mAbs

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$140,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Despite significant advances in treatment and early detection, cancer remains a significant disease threat to society. Therapeutic monoclonal antibodies are effective new treatments that have recently been developed as targeted therapies against many types of… More

A novel platform for mining the repertoire of antigen-specific B cells

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$99,635.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Cancer remains a significant threat to the health and economy of today's society. Advances in cancer research are key to cancer biomarker discovery, development of rapid and reliable methods of cancer-specific di agnosis, and development of new treatments.… More

BIOMARKER SCREENING WITH REVOLUTIONARY NEOABS

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$507,208.00
Agency:
HHS
Principal Investigator:
Tucker Ward
Abstract:
N/a

BIOMARKER SCREENING WITH REVOLUTIONARY NEOABS

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$507,208.00
Agency:
HHS
Principal Investigator:
Tucker Ward
Abstract:
N/a

BIOMARKER SCREENING WITH REVOLUTIONARY NEOABS

Award Year / Program / Phase:
2008 / SBIR / Phase II
Award Amount:
$206,777.00
Agency:
HHS
Principal Investigator:
Abstract:
Not Available

Improving Ovarian Cancer Treatment by Targeting a Novel Epitope of MUC16

Award Year / Program / Phase:
2009 / STTR / Phase I
Award Amount:
$190,591.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF WISCONSIN MADISON
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The CA125 antigen is a well known marker for monitoring the recurrence and progression of epithelial ovarian cancer. It is now clear that this antigen is a repeating peptide epitope that is present within the protein ba ckbone of the recently identified mucin… More

Reactivation of human cells for novel fully human Ab platform

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$286,368.00
Agency:
HHS
Principal Investigator:
Rachel H. Kravitz – 608-260-8190
Abstract:
DESCRIPTION (provided by applicant): Monoclonal antibodies (mAbs) have been developed into a highly effective class of therapeutic molecules, with global growth of 37% between 2001 and 2002. Since their discovery in 1975, mAbs have been described as magic bullets with the potential to seek out… More